Caasalan, Nimfa M.

HRN: 22-81-94  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/03/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
04/03/2023
04/10/2023
IV
600mg
Q6
CAP-MR; Infected Breast Mass Right
Waiting Final Action 
04/03/2023
MUPIROCIN 2%, 15G (TUBE)
04/03/2023
04/10/2023
TOPICAL
2%
BID
Infected Breast Mass, Right
Waiting Final Action 
04/07/2023
CEFTRIAXONE 1G (VIAL)
04/07/2023
04/13/2023
IV
2g
OD
Cap Mr
Waiting Final Action 
04/07/2023
MUPIROCIN 2%, 15G (TUBE)
04/07/2023
04/13/2023
TOPICAL
Apply On Affected Areas
Bid
Infected Breast Mass
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: